These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34988580)

  • 1. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
    Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer.
    Acun T; Senses KM
    Breast Cancer; 2020 May; 27(3):483-489. PubMed ID: 31902119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.